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In this issue of Cell Stem Cell, Warren et al. (2010) describe a new methodology, using synthetic mRNA, for
efficiently generating iPSCs without compromising genomic integrity. This powerful approach can also be
used for directed differentiation of iPSCs, or even for trans-differentiation to generate clinically relevant differ-
entiated cell types.The character of a fully differentiated
somatic cell is no longer considered an
irreversible terminus. We now appreciate
how the many routes toward differentia-
tion can be experimentally manipulated
to bring the cells back to an embryonic-
like pluripotent state, followed by respeci-
fication into cells of another tissue type. In
this issue of Cell Stem Cell, Warren et al.
(2010) demonstrate that both tasks can
be accomplished by synthetic mRNAs,
as long as appropriate modifications are
introduced in both the molecule and
culture conditions.
Almost 5 years ago, the Yamanaka
laboratory first demonstrated that adult
skin cells could generate embryonic-like
stem cells, known as induced pluripotent
stem cells (iPSCs) (Takahashi and Yama-
naka, 2006; Takahashi et al., 2007) simply
by enforcing ectopic expression of a
few transcription factors (reprogramming
factors [RFs]). Because iPSCs can be
also generated from somatic cells derived
from patients harboring genetic diseases
(patient-specific iPSCs), they provide
an opportunity to perform pharmacolog-
ical screens and autologous cell-based
therapy approaches.
However, before reprogrammed cells
can be considered realistic clinical tools,
several major challenges must be over-
come, not the least of which is themethod
of RF delivery into cells. The first genera-
tion of iPSCs used integrating viral vec-
tors to deliver RFs, which compromised
the integrity of the target cell genome,
and thus generated mutant iPSCs. To
overcome this hurdle, a number of strate-
gies were pursued, including (1) reprog-
ramming by protein delivery, (2) delivering
RFs via the nonintegrating Sendai virus,
(3) use of adenoviruses as vectors, and(4) using transient plasmid deliveries.
Although all of these advances improved
the technology, they did not completely
bypass the preclinical roadblock, as each
approach is still hampered by relatively
minor but specific caveats, in particular
with respect to the efficiency of reprog-
ramming. Furthermore, even when the
inserted transgenes were removed using
the Cre-LoxP system, as attempted in the
mouse, permanent modifications were
left in the host genome (Kaji et al., 2009),
again creating mutant iPSCs.
The new and innovative approach pre-
sented here addresses all of the above
concerns and provides what seems to
be the best strategy so far to reprogram
mutation-free pluripotent cells at a high
frequency (Warren et al., 2010). The
approach relies on the delivery of a cock-
tail of in vitro-generated, modified syn-
thetic mRNA that encodes the RFs (Klf4,
c-Myc, Oct4, Sox2, and Lin28). Given
that these mRNAs are translated in the
cytoplasm, their transfection into human
cells does not cause permanent genetic
changes. Interestingly, as also briefly
referenced by the authors, the introduc-
tion of synthetic mRNA as a means to
manipulate protein expression in target
cells was first used in the context of
gain-of-function experiments to dissect
early embryogenesis of the Xenopus lae-
vis (Yisraeli et al., 1989; Vize et al., 1991).
However, although this approach worked
robustly in frogs, it proved to be rather
inefficient in human cells, given that it
led to cytotoxicity due to the interferon-
mediated innate immune response and
poor protein yield. Undeterred, Rossi and
colleagues developed three main modifi-
cations of the original protocol (Warren
et al., 2010), which collectively led to theCell Stem Cell 7,resolution of these problems. The first
protocol adaptation was at the molecular
level, whereby 5-methylcytidine was
substituted for cytidine, and pseudouri-
dine for uridine, followed by phosphatase
treatment. These alterations solved the
protein yield issue, probably by stabilizing
the delivered mRNAs, and also enabled
the researchers to produce the appro-
priate RF stoichiometry. The secondmod-
ification was made at the cellular level:
the interferon response was blocked on
target cells with a Vaccinia virus decoy
protein, B18R, which inhibits type I inter-
feron and eliminated cytotoxicity. These
approaches simplify a previous protocol
based on the cotransfection of RFmRNAs
with a siRNA cocktail designed to knock
down immune-related factors (Angel
and Yanik, 2010). The final adaptation
involved changing a variety of cell cul-
ture and RF delivery conditions, which
included switching to low oxygen and
daily transfections of the modified syn-
thetic mRNAs encoding the RF factors.
Interestingly, these alterations to the pro-
tocol drastically improved both the effi-
ciency and the kinetics of reprogramming
in multiple cell types. The combination of
these thoughtful changes ultimately led
to successful RNA-mediated reprogram-
ming of target cells.
Another study, published earlier this
year, had shown that transfection of
unmodified mRNAs encoding the RFs
could induce expression of pluripotency
markers in human fibroblasts, without
suppression of the interferon response
(Yakubov et al., 2010). However, whether
these cells—termed RiPSCs—were func-
tionally pluripotent remained an open
question. Importantly, Warren et al. (2010)
show here that RiPSC lines generatedNovember 5, 2010 ª2010 Elsevier Inc. 549
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molecular and functional tests of pluripo-
tency, thus validating their identity. More-
over, in addition to their capacity to
generate progeny from all three germ
layers, RiPSC exhibited advantages rela-
tive to iPSCs obtained by viral delivery
of RFs, given that they displayed: (1)
a fast 2 week output, (2) greater homoge-
neity, and (3) a global molecular signa-
ture that clustered closer to those of
human embryonic stem cells (hESCs).
Although the long-term implications of
the findings that RiPSCs arise more
frequently and homogeneously—and with
faster kinetics—remain to be seen, the
final point emphasizes the crucial impor-
tance of using hESCs as the gold stan-
dard by which to measure the results of
comparative studies among sources of
pluripotent cells.
Also, the findings of this study demon-
strate the feasibility of the RNA-mediated
approach to support directed differentia-
tion, given that introduction of modified,
synthetic mRNA for MyoD was able to
convert RiPSCs or mesenchymal stem
cells into myotubes (Warren et al., 2010).
Further application of this technology will
lead to the simplification of RNA-medi-
ated differentiation of target cells toward
specific, desired cell fates.550 Cell Stem Cell 7, November 5, 2010 ª20Another route to change fate of one cell
into another, involves transdifferentiation,
of somatic cells without passing through
an embryonic state. This strategy was
originally utilized when ectopic expres-
sion of a single transcription factor,
MyoD, led to the transdifferentiation of
fibroblasts into terminally differentiated
myofibers (Davis et al., 1987). The parallel
approach has since been applied to
a variety of cells, such as the in vivo
conversion of mouse pancreatic exo-
crine cells to pancreatic b cells after the
delivery of three factors (Ngn3, Pdx1,
and Mafa; Zhou et al., 2008). Thus, trans-
differentiation may provide yet another
platform for cell-based therapy strategies
in clinical settings. It will be interesting to
assess whether the synthetic mRNA tech-
nology could be applied to transdifferenti-
ate adult somatic cells into useful cell
types.
The use of synthetic mRNAs to change
cell fate has come a long way since its
debut in the amphibian system. The inge-
nious adaptation of this technology to the
human system in order tomediate reprog-
ramming and directed differentiation,
including the additional problem solving
conducted by the authors in order to
derive integration-free RiPSCs, makes
the modified RNA approach a powerful10 Elsevier Inc.new tool that brings cell-based therapy
ever closer to reality.REFERENCES
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Mammalian cloning by somatic cell nuclear transfer is a notoriously inefficient process with a low birth rate.
Recently in Science, Inoue et al. (2010) report that somatic cell nuclear transfer fails to regulate Xist expres-
sion from the X chromosome.Three broad categories encompass the
varied experimental approaches used to
reprogram somatic nuclei to a pluripotent
state: cell fusion between somatic and
embryonic stem cells (ESCs), transcrip-
tion-factor transduction, and somatic
cell nuclear transfer (SCNT). Cell fusionhas been useful for exploring the regula-
tory mechanisms responsible for reprog-
ramming; however, the tetraploid nature
of fused cells prevents a stringent
in vivo test of the cell’s developmental
potential. On the other hand, induced
pluripotent stem cells (iPSCs) generatedby defined transcription-factor transduc-
tion have been successfully assayed for
their ability to generate completely stem
cell-derived embryo proper by tetraploid
embryo complementation. SCNT repro-
grams somatic cell nuclei through nuclei
introduction into enucleated oocytes,
